Puma Biotech's NERLYNX Secures Major NCCN Guidelines Recognition for Cervical ...

December 23, 2024

Puma Biotechnology announced NERLYNX® inclusion in NCCN Cervical Cancer Guidelines as a second-line therapy for HER2-mutated tumors, based on Phase II SUMMIT trial results.

Related Clinical Trials

Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations

Highlighted Terms

NERLYNX®cervical cancer recurrent or metastatic cervical cancer National Comprehensive Cancer Network neratinib Puma Biotechnology NCT01953926

Related News

stocktitan.net

Puma Biotech's NERLYNX Secures Major NCCN Guidelines Recognition for Cervical ...

Puma Biotechnology announced NERLYNX® inclusion in NCCN Cervical Cancer Guidelines as a second-line therapy for HER2-mutated tumors, based on Phase II SUMMIT trial results.